680 related articles for article (PubMed ID: 27288051)
21. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
[TBL] [Abstract][Full Text] [Related]
24. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.
Saraiya N; Yopp AC; Rich NE; Odewole M; Parikh ND; Singal AG
Aliment Pharmacol Ther; 2018 Jul; 48(2):127-137. PubMed ID: 29851093
[TBL] [Abstract][Full Text] [Related]
25. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
Virlogeux V; Pradat P; Hartig-Lavie K; Bailly F; Maynard M; Ouziel G; Poinsot D; Lebossé F; Ecochard M; Radenne S; Benmakhlouf S; Koffi J; Lack P; Scholtes C; Uhres AC; Ducerf C; Mabrut JY; Rode A; Levrero M; Combet C; Merle P; Zoulim F
Liver Int; 2017 Aug; 37(8):1122-1127. PubMed ID: 28423231
[TBL] [Abstract][Full Text] [Related]
26. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
27. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis.
Miuma S; Miyamoto J; Taura N; Fukushima M; Sasaki R; Haraguchi M; Shibata H; Sato S; Miyaaki H; Nakao K
Intern Med; 2020; 59(7):901-907. PubMed ID: 32238660
[TBL] [Abstract][Full Text] [Related]
28. Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.
Lithy RM; Elbaz T; H Abdelmaksoud A; M Nabil M; Rashed N; Omran D; Kaseb AO; O Abdelaziz A; I Shousha H
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):227-234. PubMed ID: 33208688
[TBL] [Abstract][Full Text] [Related]
29. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.
Ikenaga H; Uchida-Kobayashi S; Tamori A; Odagiri N; Yoshida K; Kotani K; Motoyama H; Kozuka R; Kawamura E; Hagihara A; Fujii H; Enomoto M; Kawada N
J Viral Hepat; 2022 Jan; 29(1):52-59. PubMed ID: 34695288
[TBL] [Abstract][Full Text] [Related]
30. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
[No Abstract] [Full Text] [Related]
32. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
[TBL] [Abstract][Full Text] [Related]
33. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study.
Dharancy S; Coilly A; Fougerou-Leurent C; Duvoux C; Kamar N; Leroy V; Tran A; Houssel-Debry P; Canva V; Moreno C; Conti F; Dumortier J; Di Martino V; Radenne S; De Ledinghen V; D'Alteroche L; Silvain C; Besch C; Perré P; Botta-Fridlund D; Francoz C; Habersetzer F; Montialoux H; Abergel A; Debette-Gratien M; Rohel A; Rossignol E; Samuel D; Duclos-Vallée JC; Pageaux GP;
Am J Transplant; 2017 Nov; 17(11):2869-2878. PubMed ID: 28898563
[TBL] [Abstract][Full Text] [Related]
34. HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management.
Nahon P; Layese R; Cagnot C; Asselah T; Guyader D; Pol S; Pageaux GP; De Lédinghen V; Ouzan D; Zoulim F; Audureau E;
Cancer Prev Res (Phila); 2021 May; 14(5):581-592. PubMed ID: 33608313
[TBL] [Abstract][Full Text] [Related]
35. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.
Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R
Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007
[TBL] [Abstract][Full Text] [Related]
36. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M
Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733
[TBL] [Abstract][Full Text] [Related]
37. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA
Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416
[TBL] [Abstract][Full Text] [Related]
38. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C.
Ahn YH; Lee H; Kim DY; Lee HW; Yu SJ; Cho YY; Jang JW; Jang BK; Kim CW; Kim HY; Park H; Cho HJ; Park B; Kim SS; Cheong JY
Gut Liver; 2021 May; 15(3):410-419. PubMed ID: 32893194
[TBL] [Abstract][Full Text] [Related]
39. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
40. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
Reig M; Mariño Z; Perelló C; Iñarrairaegui M; Ribeiro A; Lens S; Díaz A; Vilana R; Darnell A; Varela M; Sangro B; Calleja JL; Forns X; Bruix J
J Hepatol; 2016 Oct; 65(4):719-726. PubMed ID: 27084592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
